Distal cholangiocarcinoma and pancreas cancer: A 13-institution study from the U.S. extrahepatic biliary malignancy consortium and the central pancreas consortium
Cecilia G. Ethun, MD; Alexandra G. Lopez-Aguiar, MD; Timothy Pawlik, MD, MPH, PhD, FACS; and colleagues found that while distal cholangiocarcinoma (DC) and pancreatic ductal adenocarcinoma (PDAC) are distinct entities, DC has a more favorable prognosis than PDAC. Current adjuvant therapy regimens are only associated with improved survival in PDAC, not DC. Treatment paradigms used for PDAC should not be extrapolated to DC, despite similar operative approaches, and novel therapies for DC should be explored.
This article and all other JACS content is available online.
